

Anti-ADGRE2 Reference Antibody (Abbvie patent anti-EMR2)

Catalog # APR11507

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q9UHX3
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	90472


Additional Information

Target/Specificity	ADGRE2
Expression system	CHO


Protein Information

Name	ADGRE2 (HGNC:3337)
Synonyms	EMR2
Function	Cell surface receptor that binds to the chondroitin sulfate moiety of glycosaminoglycan chains and promotes cell attachment. Promotes granulocyte chemotaxis, degranulation and adhesion. In macrophages, promotes the release of inflammatory cytokines, including IL8 and TNF. Probably signals through G proteins. Is a regulator of mast cell degranulation (PubMed: 26841242).
Cellular Location	Cell membrane; Multi-pass membrane protein. Cell projection, ruffle membrane; Multi-pass membrane protein. Note=Localized at the leading edge of migrating cells.
Tissue Location	Expression is restricted to myeloid cells. Highest expression was found in peripheral blood leukocytes, followed by spleen and lymph nodes, with intermediate to low levels in thymus, bone marrow, fetal liver, placenta, and lung, and no expression in heart, brain, skeletal muscle, kidney, or pancreas. Expression is also detected in monocyte/macrophage and Jurkat cell lines but not in other cell lines tested. High expression in mast cells (PubMed:26841242)


Images



Anti-ADGRE2 Reference Antibody (Abbvie patent anti-EMR2) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.



The purity of Anti-ADGRE2 Reference Antibody (Abbvie patent anti-EMR2) is 98.3%, determined by SEC-HPLC.



HuADGRE2-FL-His-EGFP-HEK293-A11 cell line were stained with Abbvie patent anti-EMR2 and negative control protein respectively, washed and then followed by PE and analyzed with FACS, with the EC50 is 3.856 nM.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.